Document is current
Any future updates will be listed below
-
Authors
Bywater, Megan https://orcid.org/0000-0002-7466-6927
Lane, Steven W. https://orcid.org/0000-0002-8050-6209
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1195987)
- License Information
-
More Information
Article History
Received: 19 April 2022
Accepted: 10 August 2022
First Online: 26 August 2022
Competing interests
: S.W.L. has consulted for Novartis, distributor of ruxolitinib in Australia. S.W.L. and M.B. have received supply of research mouse pegylated interferon from Pharmaessentia.
